Neximmune announces formation of scientific advisory board

Gaithersburg, md., may 27, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced the formation of its scientific advisory board (sab). the sab is comprised of distinguished academic leaders in the fields of immuno-oncology, immunology and t cell biology and their expertise spans the disciplines of basic research, translational science and clinical drug development.
NEXI Ratings Summary
NEXI Quant Ranking